Selexis SA, a Geneva, Switzerland-based provider of mammalian cell-line generation technology, has entered a commercial license agreement that provides Takeda Pharmaceutical with access to research cell banks developed using Selexis’ SUREtechnology Platform, which facilitates the production of recombinant proteins, including those that are difficult-to-express in other systems.

Takeda is leveraging Selexis’ mammalian cell line-based protein expression platform to develop recombinant fusion proteins.

In June 2017, JSR Corporation, the parent company of JSR Life Sciences, agreed to acquire Selexis SA.

Source: Selexis